EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extended-release Injectable Buprenorphine Initiation in the Emergency Department

Brittany Cesar, Jessica Moore, Raluca Isenberg, Jessica Heil, Rachel Rafeq, Rachel Haroz, Matthew Salzman, Alice V Ely

Western Journal of Emergency Medicine · 12.07.2025 · 26 (4)

DOI: 10.5811/westjem.21299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Western Journal of Emergency Medicine, online erschienen am 12.07.2025. Verfasst von Brittany Cesar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cooper University Health Care - Center for Healing, Department of Addiction Medicine, Camden, New Jersey. Hauptthemen laut MEDLINE: Buprenorphine, Emergency Service, Hospital, Opioid-Related Disorders, Opiate Substitution Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Extended-release buprenorphine (XR-BUP) is a long-acting injectable medication used for the treatment of opioid use disorder (OUD). It is currently approved for use in patients who have been administered at least seven days of sublingual buprenorphine (SL-BUP). For patients with OUD who are unstable (ie, not at treatment goal, with active opioid use) or not yet on medication for OUD (MOUD) such as SL-BUP, the emergency department (ED) setting is an essential location for access to treatment. There is, as yet, no research on the utility of on-demand XR-BUP administration in the ED.

Methods

We performed a retrospective cohort study of individuals with OUD who received XR-BUP in the ED through our novel reallocation pathway. We reviewed charts from an addiction medicine specialty outpatient clinic to determine retention in treatment, continuation on XR-BUP, and reported quantitative analysis. Our primary outcome was retention in treatment, measured by subsequent XR-BUP injection after initial ED XR-BUP administration. The secondary outcome was the reason for ED administration of XR-BUP (as opposed to administration in the clinic setting).

Results

Our study population included 69 patients (68.2% male). Our primary outcome showed that 51 (73.9%) patients who had their first injection in the ED received a second XR-BUP injection and 40 (58%) received their third XR-BUP injection. Our secondary outcome showed that 7.2% had barriers with access to treatment; however, most of the patients received the injection due to instability of the treatment of the OUD (69.6%). These patients were either unable to adhere to MOUD, reported issues with the prescription, or were still using substances while on MOUD. For 52 (75%) patients, the index ED injection was their first ever XR-BUP injection. Logistical regression analyses demonstrated that clinical and demographic factors did not lead to increased attrition, while patients with other co-occurring substance use disorders were more likely to present for follow-up treatment.

Conclusion

In our retrospective study, patients who received ED-initiated extended-release buprenorphine had a strong retention rate compared to previous studies evaluating ED-initiated sublingual BUP (retention rates ranging from 16.7-60%). The ED provided a convenient healthcare access point for XR-BUP initiation. The XR-BUP is a helpful tool for achieving induction after failed SL-BUP initiation and may have further implications in minimizing treatment gaps after discharge and improving OUD treatment retention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineEmergency Service, HospitalOpioid-Related DisordersOpiate Substitution TreatmentNarcotic AntagonistsHumansRetrospective StudiesMaleFemaleAdultDelayed-Action PreparationsMiddle AgedAdministration, Sublingual

Substanzen

BuprenorphineDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • Cooper University Health Care - Center for Healing, Department of Addiction Medicine, Camden, New Jersey.
  • Cooper University Health Care, Department of Emergency Medicine, Camden, New Jersey.
  • Cooper University Health Care - Cooper Research Institute, Camden, New Jersey.
  • Cooper Medical School of Rowan University, Camden, New Jersey.

Zitieren

APA

Cesar, B., Moore, J., Isenberg, R., Heil, J., Rafeq, R., Haroz, R., Salzman, M., & Ely, A. V. (2025). Extended-release Injectable Buprenorphine Initiation in the Emergency Department. Western Journal of Emergency Medicine, 26(4). https://doi.org/10.5811/westjem.21299

Vancouver

Cesar B, Moore J, Isenberg R, Heil J, Rafeq R, Haroz R, et al. Extended-release Injectable Buprenorphine Initiation in the Emergency Department. Western Journal of Emergency Medicine. 2025;26(4). doi:10.5811/westjem.21299

BibTeX
@article{Cesar2025,
  author = {Cesar, Brittany and Moore, Jessica and Isenberg, Raluca and Heil, Jessica and Rafeq, Rachel and Haroz, Rachel and Salzman, Matthew and Ely, Alice V},
  title = {Extended-release Injectable Buprenorphine Initiation in the Emergency Department},
  journal = {Western Journal of Emergency Medicine},
  year = {2025},
  volume = {26},
  number = {4},
  doi = {10.5811/westjem.21299}
}
Kostenlos starten →